文献速递肝胆胰外科围术期管理与 ERAS

肝门部胆管癌晚期局部复发:定义、治疗与标准化

Perhilar cholangiocarcinoma late local recurrence-Time to define, treat, and standardize.
PubMed 文献 · Surgery · 2026-05-25

本文系统综述了肝门部胆管癌术后晚期局部复发的生物学与临床特征,提出以24个月为界的标准化定义,并评估了积极挽救性手术及肝移植的疗效,强调建立全球前瞻性登记以推动规范化诊疗。

要点

  • 建议将术后≥24个月出现的局部复发定义为晚期局部复发。
  • 晚期局部复发中部分病例基因组低 concordance,提示可能为新生肿瘤而非克隆性复发。
  • 遵循原发肿瘤根治标准的挽救性手术可获得接近30-40%的5年生存率。

核心结论

  • 肝门部胆管癌晚期局部复发是区别于早期转移性复发的临床实体,部分患者可能通过积极治疗获得治愈机会。

研究设计与样本

  • 系统检索PubMed(2015年以来)纳入87篇文献,其中68篇报告复发时间分析。
  • 汇总分析大型西方和亚洲队列(n>3,000)的复发时间分布。
  • 对配对原发与晚期复发肿瘤进行全外显子组测序分析基因组一致性。

主要发现

  • 文献中「晚期」复发的定义高度异质(12-60个月),妨碍了有效比较。
  • 汇总队列数据显示复发风险在约24个月后显著下降,之后出现次级平台期。
  • 配对肿瘤基因组分析显示,相当比例晚期复发突变一致性低,提示新生肿瘤发生而非克隆性复发。
  • 遵循原发肿瘤根治标准的挽救性手术(同侧半肝切除、尾状叶切除、规范门淋巴结清扫)5年生存率接近30-40%,显著优于非手术治疗。
  • 早期单中心数据显示,选择性的肝移植患者3年生存率达73%。

关键数值与推荐

  • 建议采用24个月作为晚期局部复发的标准化定义界值。
  • 挽救性手术应遵循原发肿瘤的肿瘤学原则,包括同侧半肝切除、尾状叶切除和规范门淋巴结清扫。
  • 晚期局部复发的监测影像、诊断检查和挽救治疗策略需基于循证推荐。

临床怎么用

  • 临床中应将术后≥24个月的局部复发识别为潜在可治疗的晚期局部复发,而非普遍认为的不可治愈。
  • 对符合条件的患者积极评估挽救性手术,并严格遵循肿瘤学切除标准。
  • 推动建立全球前瞻性登记(HILAR-RECURE)以标准化定义和治疗策略。

局限性

  • 文献中晚期复发定义异质性大(12-60个月),限制可比性。
  • 基因组分析中部分晚期复发突变一致性低的具体比例未在摘要中报告。
  • 肝移植数据来自早期单中心,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perihilar cholangiocarcinoma remains associated with poor long-term survival despite advances in surgical technique and perioperative care, largely due to disease recurrence. Emerging evidence suggests that recurrence follows a bimodal temporal distribution, with a distinct subset of late local recurrences occurring ≥24 months after resection. These late local recurrences appear biologically indolent and are often amenable to aggressive salvage therapy, yet remain under-recognized in current staging and surveillance frameworks. This study aimed to define the biologic and clinical characteristics of perihilar cholangiocarcinoma late local recurrences, propose a standardized diagnostic framework, and evaluate optimal treatment strategies. METHODS: systematic PubMed search was conducted using terms "perihilar∗ OR Klatskin∗" AND "recurrence" to identify original articles published since 2015. Pooled analyses from large Western and Asian cohorts (n > 3,000) were reviewed to characterize the temporal distribution of recurrence. Whole-exome sequencing data from paired primary and late recurrent tumors were analyzed to assess genomic concordance. Evidence-based recommendations for surveillance imaging, diagnostic workup, and salvage therapeutic strategies were formulated through critical synthesis of published literature. RESULTS: Among 87 identified articles, 68 reported time-to-recurrence analyses with highly variable definitions of "late" recurrence (12-60 months), precluding meaningful comparison. Pooled cohort data demonstrated a marked decrement in recurrence risk after approximately 24 months, with a secondary plateau thereafter. Genomic analyses of paired primary-recurrent tumors revealed low mutational concordance in a substantial proportion of late recurrences, suggesting de novo tumorigenesis rather than clonal relapse. Salvage surgery adhering to primary oncological standards (ipsilateral hemihepatectomy, caudate lobectomy, formal portal lymphadenectomy) achieved 5-year survival rates approaching 30-40%, significantly superior to nonoperative management. Liver transplantation for selected patients demonstrated 3-year survival of 73% in early single-center data. CONCLUSION: Perihilar cholangiocarcinoma late local recurrence represents a clinically meaningful and potentially curable entity distinct from early metastatic relapse. Adoption of a standardized 24-month definition, rigorous application of oncological principles in salvage surgery, and establishment of a global prospective registry (HILAR-RECURE) are essential to transform late local recurrence from an anecdotal observation into a reproducible therapeutic opportunity.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Huang J, Wu T. Perhilar cholangiocarcinoma late local recurrence-Time to define, treat, and standardize. Surgery. 2026. PMID: 42296666. doi:10.1016/j.surg.2026.110341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。